Sandostatin and Light chain analysis increased - a phase IV clinical study of FDA data

Summary:

Light chain analysis increased is reported as a side effect among people who take Sandostatin (octreotide acetate), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Linagliptin, and have High blood pressure.

The phase IV clinical study analyzes which people have Light chain analysis increased when taking Sandostatin. It is created by eHealthMe based on reports of 46,692 people who have side effects when taking Sandostatin from the FDA, and is updated regularly.

What is Sandostatin?

Sandostatin has active ingredients of octreotide acetate. It is often used in acromegaly. eHealthMe is studying from 46,793 Sandostatin users. Check the latest studies of Sandostatin.

What is Light chain analysis increased?

Light chain analysis increased is found to be associated with 196 drugs and 149 conditions by eHealthMe. Check the latest studies of Light chain analysis increased.

On Jul, 17, 2026

46,692 people reported to have side effects when taking Sandostatin.
Among them, 16 people (0.03%) have Light chain analysis increased.

Could Sandostatin cause Light chain analysis increased?

Among these 16 people:

How long have people been on Sandostatin when they have Light chain analysis increased? *

What is the gender of people who have Light chain analysis increased when taking Sandostatin? *

female: 100 %
male: 0.0 %

What is the age of people who have Light chain analysis increased when taking Sandostatin? *

What are other drugs people take besides Sandostatin? *

Micardis: 15 people, 93.75%
Gliclazide: 15 people, 93.75%
Linagliptin: 15 people, 93.75%
Amlodipine: 11 people, 68.75%
Sinemet: 8 people, 50.00%
Metformin: 7 people, 43.75%
Signifor Lar: 6 people, 37.50%
Carbidopa And Levodopa: 2 people, 12.50%
Actonel: 2 people, 12.50%
Vitamin B: 2 people, 12.50%

What are other side effects people have besides Light chain analysis increased? *

White Blood Cell Count Decreased: 15 people, 93.75%
Gallstones (stone formation by bile component): 15 people, 93.75%
Dizziness: 15 people, 93.75%
Dry Skin: 15 people, 93.75%
Faeces Discolored: 15 people, 93.75%
Fall: 15 people, 93.75%
Fatigue (feeling of tiredness): 15 people, 93.75%
Gait Disturbance: 15 people, 93.75%
Glycosylated Haemoglobin Increased: 15 people, 93.75%
High Blood Pressure: 15 people, 93.75%

What are the existing conditions these people have? *

Type 2 Diabetes: 15 people, 93.75%
High Blood Pressure: 15 people, 93.75%
Parkinson's Disease: 8 people, 50.00%
Blood Glucose Abnormal: 6 people, 37.50%
Multiple Myeloma (cancer of the plasma cells): 1 person, 6.25%

* Approximation only. Some reports may have incomplete information.

Do you take Sandostatin and have Light chain analysis increased?

- Check whether Light chain analysis increased is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Sandostatin:

Sandostatin (46,793 reports)

Browse all side effects of Sandostatin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Light chain analysis increased:

Light chain analysis increased (196 drugs)

Browse all the conditions that are associated with Light chain analysis increased:

Light chain analysis increased (149 conditions)

Related publications that referenced our studies

Saif MW, "Rheumatoid arthritis associated with the use of Sandostatin? LAR? depot in a patient with pancreatic neuroendocrine tumor", An association or a coincidence? The first case report, 2017 Jan .
Azkur D, Yoldas T, Toyran M, Kocabas CN, "A pediatric case of anaphylaxis due to octreotide", Asian Pacific journal of allergy and immunology, 2011 Dec .
Saif MW, "Rheumatoid arthritis associated with the use of Sandostatin? LAR? depot in a patient with pancreatic neuroendocrine tumor", An association or a coincidence? The first case report, 2017 Jan .
Azkur D, Yoldas T, Toyran M, Kocabas CN, "A pediatric case of anaphylaxis due to octreotide", Asian Pacific journal of allergy and immunology, 2011 Dec .

How the study uses the data?

The study uses data from the FDA. It is based on octreotide acetate (the active ingredients of Sandostatin) and Sandostatin (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.